<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619993</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-040369</org_study_id>
    <nct_id>NCT03619993</nct_id>
  </id_info>
  <brief_title>Patient Preference for Pegfilgrastim (Neulasta®) Application Forms</brief_title>
  <acronym>CONVENIENCE</acronym>
  <official_title>A Comparison of Pegfilgrastim (Neulasta®) Application Via Manual Injection Versus Injection Via an On-body Injector Regarding Patient Preference and Health Economics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare two application forms (pre-filled syringe and On-body injector) of
      the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient
      preference and health economics. Chemotherapy will be supported with pegfilgrastim for four
      subsequent chemotherapy cycles using alternating application forms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neutropenia is one of the most common side effects of myelosuppressive chemotherapy. Febrile
      neutropenia and infectious complications are associated with chemotherapy dose delays and
      reductions and an increased risk of hospitalization. Prophylaxis with recombinant G-CSFs
      reduces the incidence, severity and duration of CIN and the risk of developing FN.
      Pegfilgrastim is available for over 10 years and is specified in the SmPC to be applied at
      least 24 hours after cytotoxic chemotherapy. For this application patients often have to
      return to their physician one day after chemotherapy treatment for the sole purpose of
      receiving pegfilgrastim subcutaneous (s.c.) injection. For different reasons, some of the
      patients requiring pegfilgrastim may not be able to return at this day and thus may not
      receive pegfilgrastim in accordance with the SmPC. The On-body injector for pegfilgrastim
      provides an option for patients not to return to the clinic/medical office the day after
      chemotherapy for their pegfilgrastim injection. The kit includes a single-use prefilled
      syringe co-packed with the On-body injector for pegfilgrastim. The On-body injector is
      applied to the patient's skin at the day of chemotherapy treatment and it automatically
      delivers pegfilgrastim approximately 27 h after the On-body injector was applied to the
      patient`s skin.

      Patient-reported outcomes on preference for either application form can help to guide
      physicians' treatment choice, particularly in terms of application of the same active
      substance, in this study pegfilgrastim.

      This study aims to compare the two application forms of pegfilgrastim (pegfilgrastim
      pre-filled syringe vs. On-body injector for pegfilgrastim) with regard to patient preference
      and health economy. A trial design with randomization of patients to receive the two
      application forms of pegfilgrastim in an alternating sequence for 4 cycles starting with
      either On-body injector for pegfilgrastim (Arm A) or pegfilgrastim pre-filled syringe (Arm B)
      was chosen. In this way, all patients will receive both application forms in order to be able
      to decide for their individual preference. Four cycles (that means each patient will receive
      each application form of pegfilgrastim twice) should be a sufficient number for the patient
      to make a decision. This design with two treatment arms serves to exclude a systematic bias
      that might be generated when starting with the same application form for all patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">September 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference for type of pegfilgrastim application assessed via project specific survey answered after 4 applications.</measure>
    <time_frame>4 cycles of chemotherapy, i.e. 8 to 12 weeks (depending on chemotherapeutic regimen)</time_frame>
    <description>Percentage of patients favoring pegfilgrastim application via On-body injector. Patients are answering the questionnaire after 4 applications of pegfilgrastim in total, with On-body injector and pre-filled syringes used in alternating sequence (each type of application administered two times in total).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time point of pegfilgrastim application within a chemotherapy cycle</measure>
    <time_frame>4 cycles of chemotherapy, i.e. 8 to 12 weeks (depending on chemotherapeutic regimen)</time_frame>
    <description>The number of hours between chemotherapy application and pegfilgrastim application in each of the 4 observed chemotherapy cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference for pegfilgrastim application assessed via project specific survey answered at time of enrollment</measure>
    <time_frame>at enrollment</time_frame>
    <description>Percentage of patients favoring pegfilgrastim application via On-body injector. Patients are answering the questionnaire before initial application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of type of pegfilgrastim application on daily life of the patient assessed by direct questioning using project specific patient survey.</measure>
    <time_frame>4 cycles of chemotherapy, i.e. 8 to 12 weeks (depending on chemotherapeutic regimen)</time_frame>
    <description>Percentage of patients reporting a certain impact level with respect to the type of pegfilgrastim application. Patient questionnaires will be answered after pegfilgrastim application in each of the 4 observed chemotherapy cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of nurses favoring pegfilgrastim application via On-body injector at study start and at end of study as stated via a project specific nurse survey</measure>
    <time_frame>from first enrollment to end of study of last patient at a site (= end of cycle 4 of last patient, expected to be latest 2.5 years after study start)</time_frame>
    <description>Percentage of nurses favoring pegfilgrastim application via On-body injector. Nurses are answering the questionnaire at study start and at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preference of investigators for either type of pegfilgrastim application at study start und at end of study assessed via project specific investigator survey</measure>
    <time_frame>from first enrollment to end of study of last patient at a site (= end of cycle 4 of last patient, expected to be latest 2.5 years after study start)</time_frame>
    <description>Percentage of investigators favoring pegfilgrastim application via On-body injector. Investigators are answering the questionnaire at study start and at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost factors for the health care system for both types of application of pegfilgrastim</measure>
    <time_frame>4 cycles of chemotherapy, i.e. 8 to 12 weeks (depending on chemotherapeutic regimen)</time_frame>
    <description>Cost factors are assessed via project specific patient survey addressing time, travel expenses and support needed to receive pegfilgrastim application.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resource utilization at site for either type of application assessed via project specific study nurse survey</measure>
    <time_frame>at end of study of last patient at a site (= end of cycle 4 of last patient, expected to be latest 2.5 years after study start)</time_frame>
    <description>Resource utilization at site is assessed via study nurse questionnaire addressing involvement of site staff and further site resources to apply pegfilgrastim.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Start with On-body injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Start with pre-filled syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-body injector</intervention_name>
    <description>Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.</description>
    <arm_group_label>Arm A: Start with On-body injector</arm_group_label>
    <arm_group_label>Arm B: Start with pre-filled syringe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pre-filled syringe</intervention_name>
    <description>For subcutaneous injection of a supportive medicine (Pegfilgrastim).</description>
    <arm_group_label>Arm A: Start with On-body injector</arm_group_label>
    <arm_group_label>Arm B: Start with pre-filled syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with early breast cancer planned to receive 3 weekly or dose-dense
             anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy
             regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21
             immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis
             with pegfilgrastim for the prevention of FN and reduction in CIN duration. Patients
             have to be included before start of their (immuno-) chemotherapy.

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0, 1 or 2

          -  Life expectancy &gt; 3 months

          -  Absolute neutrophil count ≥ 1.5 x 109/L

          -  Ability to read and understand German

          -  Signed informed consent

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Subject is currently enrolled or has not yet completed at least 30 days since ending
             other investigational device or drug trial(s) or is receiving investigational agent(s)

          -  Active infection or any serious underlying medical condition, which would impair the
             ability of the patient to receive protocol treatment

          -  Prior bone marrow or stem cell transplantion

          -  Subject of child-bearing potential is evidently pregnant (e.g. positive HCG (Human
             Chorionic Gonadotropin) test) or is breast feeding

          -  Subject is not using adequate contraceptive precautions.

          -  Other conditions which, in the opinion of the investigator, make participation in an
             investigational trial of this nature a poor risk

          -  Concerns for subject's compliance with the protocol procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Metz, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>OSP Göttingen - Gemeinschaftspraxis Dres. Meyer, Ammon, Metz und Müller</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt an der Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Georgsmarienhütte</city>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halberstadt</city>
        <zip>38820</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hildburghausen</city>
        <zip>98646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <zip>34119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köthen</city>
        <zip>06366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mayen</city>
        <zip>56727</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moers</city>
        <zip>47441</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mühlhausen</city>
        <zip>99974</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mülheim an der Ruhr</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neunkirchen</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neustadt In Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nordhorn</city>
        <zip>48527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Offenbach am Main</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Passau</city>
        <zip>94036</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plauen</city>
        <zip>08525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ratingen</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singen</city>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spremberg</city>
        <zip>03130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stolberg</city>
        <zip>52222</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sömmerda</city>
        <zip>99610</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>R-CHOP</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Early breast cancer</keyword>
  <keyword>Anthracycline/cyclophosphamide</keyword>
  <keyword>1st line</keyword>
  <keyword>immunochemotherapy</keyword>
  <keyword>taxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

